Physician profile
Danielle E Stonebraker
NPI 1194142422
$6,426.29
in general payments reported to CMS, 2019-2025
14 companies · $251 in 2025
The $251 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $548 · 2022: $895 · 2023: $4,614 · 2024: $117 · 2025: $251.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $4,239 · Food and Beverage: $744.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $4,239.00 |
| Food and Beverage | $744.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz North America, INC. | $5,721.30 | 2021-2025 | Xeomin |
| Gilead Sciences, INC. | $154.13 | 2021-2022 | |
| Abbvie INC. | $147.16 | 2021-2022 | |
| Nestle Healthcare Nutrition INC. | $80.37 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $70.33 | 2022 | |
| Intra-Sana Laboratories | $68.48 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $36.70 | 2022 | |
| Qol Medical, LLC | $34.00 | 2022 | |
| Intercept Pharmaceuticals, INC. | $32.15 | 2021-2022 | |
| Regeneron Healthcare Solutions, INC. | $21.48 | 2022 | |
| Celgene Corporation | $18.32 | 2022 | |
| Braintree Laboratories, INC. | $16.26 | 2022 | |
| Ardelyx, INC. | $13.84 | 2022 | |
| Merck Sharp & Dohme LLC | $11.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danielle Stonebraker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.